Skip to content

Investigating topical steroid withdrawal: a newly recognised medical condition

Molecular investigation of topical steroid withdrawal: a newly recognised medical condition

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ISRCTN
Registry ID
ISRCTN49789010
Enrollment
1050
Registered
2025-10-21
Start date
2025-12-01
Completion date
Unknown
Last updated
2025-11-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Topical steroid withdrawal (TSW) Injury, Occupational Diseases, Poisoning

Interventions

• Collect information from up to 1000 UK residents who have experienced TSW through an online survey. • Collect and analyse saliva samples from 50 people who are experiencing TSW, and 50 healthy volun

Sponsors

University of Edinburgh
Lead Sponsor
NHS Lothian
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: For all TSW sections of the study: 1. Self-identify as currently or previously experiencing TSW 2. Aged 18 years or older 3. Resident in the UK 4. Able to give written informed consent For TSW saliva, blood, or skin biopsy donation: 1. Must currently meet NIH TSW criteria, as assessed by the research team using questionnaire data. For healthy volunteer saliva donation: 1. Aged 18 years or older 2. Resident in the UK

Exclusion criteria

Exclusion criteria: For TSW or healthy volunteer saliva, blood, or skin biopsy donation: 1. Pregnancy 2. Uncontrolled medical illness, eg diabetes, ischaemic heart disease, active infection 3. Current use of topical or systemic steroids (i.e. must be currently in steroid withdrawal phase)

Design outcomes

Primary

MeasureTime frame
1. Topical steroid withdrawal (TSW) cohort characteristics measured using data collected from an online survey at the time of the survey. These characteristics include historical skin health and topical steroid use, symptoms and timeline of TSW, clinical management of TSW, understanding of TSW and impact of TSW. 2. Salivary cortisol levels will be measured by immunoassay using the saliva samples at one time point. 3. Blood and skin samples will be stored pending approval for use in future planned research.

Secondary

MeasureTime frame
There are no secondary outcome measures

Countries

Scotland, United Kingdom

Contacts

Public ContactSara Brown
sara.brown@ed.ac.uk+44 (0)131 651 8734

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026